102.78
전일 마감가:
$102.56
열려 있는:
$103.34
하루 거래량:
1.54M
Relative Volume:
0.42
시가총액:
$18.72B
수익:
$381.03M
순이익/손실:
$-1.01B
주가수익비율:
-17.27
EPS:
-5.95
순현금흐름:
$-789.25M
1주 성능:
+0.87%
1개월 성능:
+0.10%
6개월 성능:
+33.92%
1년 성능:
+35.29%
Insmed Inc Stock (INSM) Company Profile
명칭
Insmed Inc
전화
908-977-9900
주소
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
INSM을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
INSM
Insmed Inc
|
102.78 | 19.35B | 381.03M | -1.01B | -789.25M | -5.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-13 | 개시 | Jefferies | Buy |
2025-02-25 | 개시 | RBC Capital Mkts | Outperform |
2024-04-23 | 개시 | Truist | Buy |
2024-02-15 | 개시 | Wolfe Research | Outperform |
2023-12-08 | 개시 | Wells Fargo | Overweight |
2023-11-20 | 재개 | JP Morgan | Overweight |
2023-07-26 | 개시 | Guggenheim | Buy |
2022-12-09 | 개시 | Mizuho | Buy |
2022-12-07 | 개시 | Barclays | Overweight |
2022-11-18 | 개시 | BofA Securities | Buy |
2022-04-27 | 개시 | Goldman | Buy |
2021-12-06 | 개시 | JP Morgan | Overweight |
2021-10-19 | 재개 | Monness Crespi & Hardt | Buy |
2021-10-19 | 재개 | Morgan Stanley | Overweight |
2021-10-08 | 개시 | Cantor Fitzgerald | Overweight |
2021-04-26 | 재개 | Credit Suisse | Outperform |
2020-12-17 | 개시 | Berenberg | Buy |
2020-10-12 | 재개 | Stifel | Buy |
2019-09-03 | 개시 | Goldman | Buy |
2019-04-09 | 재확인 | H.C. Wainwright | Buy |
2019-02-15 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
2019-01-17 | 업그레이드 | Goldman | Neutral → Buy |
2019-01-02 | 개시 | Canaccord Genuity | Buy |
2018-08-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
2018-07-23 | 개시 | Goldman | Neutral |
2018-04-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2018-03-21 | 개시 | Morgan Stanley | Overweight |
2018-01-18 | 개시 | Credit Suisse | Neutral |
2017-09-05 | 재확인 | Evercore ISI | Outperform |
2017-08-17 | 개시 | Evercore ISI | Outperform |
2017-07-11 | 개시 | Robert W. Baird | Outperform |
2016-03-15 | 개시 | Stifel | Buy |
2015-11-09 | 다운그레이드 | UBS | Buy → Neutral |
2015-10-06 | 재확인 | H.C. Wainwright | Buy |
2015-06-09 | 개시 | Citigroup | Neutral |
2014-03-26 | 재확인 | HC Wainwright | Buy |
모두보기
Insmed Inc 주식(INSM)의 최신 뉴스
What drives Insmed Incorporated stock pricePowerful market insights - Autocar Professional
What analysts say about Insmed Incorporated stockMarket-beating performance - PrintWeekIndia
Is Insmed Incorporated a good long term investmentOver 200% growth - Autocar Professional
Insmed's Trading Volume Drops 46% to $208 Million Ranking 490th in Market - AInvest
Insmed (INSM) Target Price Raised by Morgan Stanley | INSM Stock News - GuruFocus
Insmed price target raised to $108 from $102 at Morgan Stanley - TipRanks
Insmed (INSM) Price Target Raised to $108 by Morgan Stanley | IN - GuruFocus
What makes Insmed Incorporated stock price move sharplyFree Capital Allocation Plans - beatles.ru
Insmed chief legal officer Smith sells $167,755 in stock By Investing.com - Investing.com Canada
Insmed chair and CEO Lewis sells $699k in shares By Investing.com - Investing.com Canada
Jim Cramer Calls Insmed "Very Speculative" - Yahoo Finance
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Benzinga
Insmed Surges to 292nd in Trading Volume with $31.9 Million Turnover - AInvest
Cramer Says Tesla Dominates While Ouster Is 'Too Speculative' - Benzinga
Insmed(INSM.US) Officer Sells US$5.54 Million in Common Stock - 富途牛牛
JPMorgan Elevates Insmed (INSM) Target Price Amid Positive Outlo - GuruFocus
A Glimpse Into The Expert Outlook On Insmed Through 12 Analysts - Nasdaq
RBC Capital Keeps Their Buy Rating on Insmed (INSM) - The Globe and Mail
United Therapeutics Faces Key Moment With Tyvaso's Q3 Results - Finimize
Insmed Incorporated(NasdaqGS: INSM) added to Russell Small Cap Comp Value Index - MarketScreener
Insmed Incorporated: Riding the Russell Reconstitution Wave in Small-Cap Biotech - AInvest
Insmed Surges to 134th in Trading Volume with $612 Million Day Despite Stock Decline - AInvest
Here’s how Insmed grows to be the next $100 billion biotech - statnews.com
Insmed's Insider Sell-Off: Strategic Exit or Buying Opportunity Ahead of Breakthrough Data? - AInvest
Pulmonary Arterial Hypertension Market Set to Grow Substantially Through 2034, DelveInsight Projects | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros - Barchart.com
Russell Rebalance: 3 Stocks Ready to Move Higher - MarketBeat
Insider Sell: Roger Adsett Sells 10,686 Shares of Insmed Inc (INSM) - GuruFocus
Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110 - Insider Monkey
10 Best Growth Stocks to Buy According to Billionaires - Insider Monkey
Wells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107 - Insider Monkey
Goldman Sachs Hikes Insmed (INSM) Price Target to $112 Affirms Buy Rating - Insider Monkey
Is Insmed Stock Overvalued at $98? - Nasdaq
Insmed Completes $750 Million Follow-On Public Offering - Global Legal Chronicle
Is Insmed Stock Overvalued After The 45% Jump? - Forbes
Oracle, AST SpaceMobile And Halliburton Are Among Top 10 Large Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga
Insmed Inc (INSM) Soars 30% on Impressive Study - MSN
Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results - Insider Monkey
INSM September 19th Options Begin Trading - Nasdaq
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans - Yahoo Finance
Insmed (INSM) Soars After Raising $650 million - MSN
Insmed Stock Jumps 29% on Encouraging PAH Study Results - MSN
Finance Watch: Insmed Cashes In On Positive Data With $750m Offering - insights.citeline.com
SEC Form 424B5 filed by Insmed Incorporated - Quantisnow
Insmed prices capital raise of $750 via stock offering - MSN
Insmed announces $650M public offering of common stock - MSN
Insmed Stock Ends Volatile Session Lower, Pauses After Monumental 32% Weekly Surge - Daily Chhattisgarh News
Insmed Inc (INSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Insmed Inc 주식 (INSM) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Lewis William | Chair and CEO |
Jul 15 '25 |
Sale |
102.37 |
6,830 |
699,220 |
233,924 |
Smith Michael Alexander | Chief Legal Officer |
Jul 15 '25 |
Sale |
102.51 |
933 |
95,642 |
66,394 |
Smith Michael Alexander | Chief Legal Officer |
Jul 11 '25 |
Sale |
96.41 |
748 |
72,115 |
67,327 |
자본화:
|
볼륨(24시간):